Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Proxalutamide  COVID-19 treatment studies for Proxalutamide  C19 studies: Proxalutamide  Proxalutamide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Proxalutamide study #2   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 84% Imp. Relative Risk, 95% CI Mechanical ventilation 89% Disease progression 78% Recovery 72% Recovery time 50% no CI Hospitalization time 33% no CI Cadegiani: Efficacy of Proxalutamide in Hospitalized COVI.. c19proxalutamide.com/cadegiani3.html Favors proxalutamide Favors control
3/10 Late treatment study
Cadegiani et al., medRxiv, doi:10.1101/2021.06.22.21259318 (results 3/10/21) (Preprint)
Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
Source   PDF   Share   Tweet
RCT 645 hospitalized patients, 317 treated with proxalutamide, showing significantly lower mortality and faster recovery with treatment. NCT04728802.
risk of death, 84.0% lower, RR 0.16, p < 0.001, treatment 35 of 317 (11.0%), control 197 of 328 (60.1%), adjusted per study.
risk of mechanical ventilation, 88.8% lower, RR 0.11, p < 0.001, treatment 4 of 317 (1.3%), control 37 of 328 (11.3%).
risk of disease progression, 77.8% lower, RR 0.22, p < 0.001, treatment 36 of 317 (11.4%), control 168 of 328 (51.2%).
risk of no recovery, 72.5% lower, RR 0.28, p < 0.001, treatment 46 of 317 (14.5%), control 173 of 328 (52.7%).
recovery time, 50.0% lower, relative time 0.50, treatment 317, control 328.
hospitalization time, 33.3% lower, relative time 0.67, treatment 317, control 328.
Cadegiani et al., 3/10/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, 30 authors.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit